Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The French pharma company Servier ...

Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing ...

Tara covers the business of health care. Her stories focus on hospitals, doctors, and how their business practices affect patients — especially when private equity gets involved. She also writes about ...

What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The Knicks are in the NBA Finals and nothing can dampen my joy, not even if the NBA commissioner suggests “objective calls” ...

In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies ...

Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost ...

The company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.